Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Weekly Modal Summary report shows your last seven days of glucose readings summarized in a
24-hour line graph format to help find patterns during the day.
- The blue line is the average of the last seven days of your readings in an hour time block.
- The red bars show the highest and lowest actual readings in the same hour time block.
- The red horizontal dotted lines are your pre-set High and Low Glucose Alert levels.
- The green horizontal dotted lines are your pre-set High and Low Glucose Target levels.
This report also provides summary statistics (average readings, standard deviation of readings), glucose target performance (percent within, above and below glucose target levels), and glucose reading highs and lows (percent of readings that fall within the low and high glucose target levels).
The information is shown based on mealtime slots.
Our pre-qualification form will ask you a few questions about your diabetes type, therapy and your current insurance provider - this will allow us to tell you what your insurance may cover for Eversense. Our Eversense Expert will then get in touch with you to confirm your details and submit the claim to your insurance provider and work directly with your health care provider and a distribution partner to order your Eversense 365 CGM.
The Eversense® E3 Smart Transmitter is a removable transmitter worn externally over the sensor. It wirelessly powers the sensor and collects glucose data via Near-Field Communication (NFC). It wirelessly sends glucose data (via Bluetooth) to the Eversense® Mobile App. It has a rechargeable battery and is warranted for one year.
Eversense 365 gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by a healthcare provider. The smart transmitter sits above the sensor, sending glucose data to your app. Want to learn more about the science behind Eversense? Check out our “How Eversense Works” video!
No, clinical study data (PROMISE Study) did not indicate this.
The Eversense® E3 Sensor is a miniaturized fluorometer that uses fluorescent intensity to measure glucose in interstitial fluid. The sensor is implanted subcutaneously (under the skin) on the upper arm, leaving no part of the sensor protruding from the skin. The sensor remains in place and provides
CGM measurements for the operating life of the sensor for up to 180 days.
The sensor is encased in a biocompatible material and utilizes a unique fluorescent, glucose indicating polymer. A light emitting diode embedded in the sensor excites the polymer, and the polymer then rapidly signals changes in glucose concentration via a change in light output. The measurement is then relayed to the smart transmitter. Measurements are completed automatically and require no action by the user.
The sensor is approximately 3.5 mm x 18.3 mm and has a silicone ring that contains a small amount of dexamethasone acetate, an anti-inflammatory steroid drug. The dexamethasone acetate minimizes inflammatory responses, very similar to common medical devices, such as pacemakers.
The Eversense E3 Sensor includes the sacrificial boronic acid (SBA) design modification.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1